Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + lenalidomide-based therapy in newly diagnosed primary plasma cell leukemia
2013-005157-75Phase 2Active
- Sponsor
- HOVON
- Start
- Oct 2014
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib and lenalidomide in plasma cell leukaemia (PCL), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Oct 2014; status: active.
02
Drugs
carfilzomiblenalidomide
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on 2013-005157-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005157-75.